Patents by Inventor Frederick Christians
Frederick Christians has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11931513Abstract: A patient interface for delivery of a supply of pressurised air or breathable gas to an entrance of a patient's airways comprising: a cushion member that includes a retaining structure and a seal-forming structure permanently connected to the retaining structure; a frame member attachable to the retaining structure; and a positioning and stabilising structure attachable to the frame member.Type: GrantFiled: December 19, 2022Date of Patent: March 19, 2024Assignee: ResMed Pty LtdInventors: Rupert Christian Scheiner, William Laurence Hitchcock, Anthony Paul Barbara, Adam Francis Barlow, Craig David Edwards, Lachlan Richard Goldspink, Kirrily Michele Haskard, Murray William Lee, Frederick Arlet May, Gerard Michael Rummery, Shiva Kumar Shanmuga Sundara, Chia Ik Tan, Stewart Joseph Wagner, Alicia Kristianne Wells, Martin Forrester, Ralph Jourdan
-
Publication number: 20230081264Abstract: The present disclosure provides methods and compositions for microglia replacement therapy in a subject in need thereof. In some cases, the method involves administering myeloid cells to the central nervous system of a subject. In some cases, the myeloid cells are derived from embryonic or extraembryonic tissue. In some cases, the myeloid cells are genetically modified. The genetic modification may include a colony stimulating factor 1 receptor (CSF1R) variant that is resistant to a CSF1R inhibitor, yet retains sensitivity to its ligand (e.g., CSF1, IL34).Type: ApplicationFiled: September 10, 2019Publication date: March 16, 2023Inventors: Frederick Christian Bennett, Peter A. Thompson, Mariko L. Bennett, Andy J. Jennings
-
Publication number: 20170298338Abstract: Fusion proteins having thermostable blunt-end ligase activity are provided. Blunt-end ligases are useful for DNA amplification, sequencing, production of recombinant DNA and recombinant fusion proteins, and other purposes. These thermostable blunt-end DNA ligases are useful in ligation schemes which include, e.g., an incubation at about 60-65° C. or higher, or as high as about 94° C., or at other temperatures. The ligases disclosed herein may enable high temperature blunt-end ligation without need for molecular crowding agents, and so may be useful for many nucleic acid ligation-amplification schemes, e.g., ones which operate at a uniform temperature (e.g., at about 60° C. or higher), including ones which require temperature cycling, e.g., from about 94° C. to about 60° C. (or higher) for one, two, three, or more cycles.Type: ApplicationFiled: February 24, 2017Publication date: October 19, 2017Inventor: Frederick Christians
-
Patent number: 9719081Abstract: Fusion proteins having thermostable blunt-end ligase activity are provided. Blunt-end ligases are useful for DNA amplification, sequencing, production of recombinant DNA and recombinant fusion proteins, and other purposes. These thermostable blunt-end DNA ligases are useful in ligation schemes which include, e.g., an incubation at about 60-65° C. or higher, or as high as about 94° C., or at other temperatures. The ligases disclosed herein may enable high temperature blunt-end ligation without need for molecular crowding agents, and so may be useful for many nucleic acid ligation-amplification schemes, e.g., ones which operate at a uniform temperature (e.g., at about 60° C. or higher), including ones which require temperature cycling, e.g., from about 94° C. to about 60° C. (or higher) for one, two, three, or more cycles.Type: GrantFiled: January 20, 2016Date of Patent: August 1, 2017Assignee: Theranos, Inc.Inventor: Frederick Christians
-
Publication number: 20170015989Abstract: Fusion proteins having thermostable blunt-end ligase activity are provided. Blunt-end ligases are useful for DNA amplification, sequencing, production of recombinant DNA and recombinant fusion proteins, and other purposes. These thermostable blunt-end DNA ligases are useful in ligation schemes which include, e.g., an incubation at about 60-65° C. or higher, or as high as about 94° C., or at other temperatures. The ligases disclosed herein may enable high temperature blunt-end ligation without need for molecular crowding agents, and so may be useful for many nucleic acid ligation-amplification schemes, e.g., ones which operate at a uniform temperature (e.g., at about 60° C. or higher), including ones which require temperature cycling, e.g., from about 94° C. to about 60° C. (or higher) for one, two, three, or more cycles.Type: ApplicationFiled: January 20, 2016Publication date: January 19, 2017Inventor: Frederick Christians
-
Publication number: 20160186164Abstract: Thermostable blunt-end ligases suitable for use in nucleic acid ligation reactions at elevated temperatures are provided. The ligases comprise fusion proteins including a DNA ligase and a DNA binding protein, e.g., a T4 DNA ligase with an N-terminal p50 fusion. The fusion proteins may include peptide linkers, peptide mimetics, terminal additions, tag peptides, D-amino acids, sugars, non-amino acid organic moieties, and polymers. The ligases are suitable for use in ligation reactions, including uniform-temperature ligation reactions, performed at about 60° C. or higher, e.g., at about 75° C. The ligases are suitable for use in nucleic acid amplification schemes with temperature cycling, e.g., temperature cycles to about 60° C. or higher, or temperature cycles from about 94° C. to about 60° C. Such nucleic acid amplification schemes may include one, two, three, or more temperature cycles. Methods of using the ligases, and articles of manufacture comprising the ligases are provided.Type: ApplicationFiled: September 4, 2015Publication date: June 30, 2016Inventor: Frederick Christians
-
Patent number: 9273301Abstract: Fusion proteins having thermostable blunt-end ligase activity are provided. Blunt-end ligases are useful for DNA amplification, sequencing, production of recombinant DNA and recombinant fusion proteins, and other purposes. These thermostable blunt-end DNA ligases are useful in ligation schemes which include, e.g., an incubation at about 60-65° C. or higher, or as high as about 94° C., or at other temperatures. The ligases disclosed herein may enable high temperature blunt-end ligation without need for molecular crowding agents, and so may be useful for many nucleic acid ligation-amplification schemes, e.g., ones which operate at a uniform temperature (e.g., at about 60° C. or higher), including ones which require temperature cycling, e.g., from about 94° C. to about 60° C. (or higher) for one, two, three, or more cycles.Type: GrantFiled: March 15, 2014Date of Patent: March 1, 2016Assignee: Theranos, Inc.Inventor: Frederick Christians
-
Publication number: 20140273102Abstract: Fusion proteins having thermostable blunt-end ligase activity are provided. Blunt-end ligases are useful for DNA amplification, sequencing, production of recombinant DNA and recombinant fusion proteins, and other purposes. These thermostable blunt-end DNA ligases are useful in ligation schemes which include, e.g., an incubation at about 60-65° C. or higher, or as high as about 94° C., or at other temperatures. The ligases disclosed herein may enable high temperature blunt-end ligation without need for molecular crowding agents, and so may be useful for many nucleic acid ligation-amplification schemes, e.g., ones which operate at a uniform temperature (e.g., at about 60° C. or higher), including ones which require temperature cycling, e.g., from about 94° C. to about 60° C. (or higher) for one, two, three, or more cycles.Type: ApplicationFiled: March 15, 2014Publication date: September 18, 2014Applicant: Theranos, Inc.Inventor: Frederick Christians
-
Publication number: 20060216724Abstract: Methods of preparing normalized mixtures from a plurality of nucleic acid samples are disclosed. Nucleic acids are amplified so that similar amounts of a target nucleic acid are generated in a plurality of different reactions. Separate amplification reactions are performed to amplify the same or different targets in a plurality of different reactions. The amounts of amplified product are approximately normalized during the amplification without the need to empirically measure the amount of amplified target.Type: ApplicationFiled: July 29, 2005Publication date: September 28, 2006Applicant: Affymetrix, INC.Inventors: Frederick Christians, Sean Walsh, Rui Mei
-
Publication number: 20060073506Abstract: The present invention provides methods for marking nucleic acid samples with detectable markers by adding different combinations of marker molecules to each sample. Each sample may be marked with a different combination of two or more marker molecules each carrying a different tag nucleic acid sequences. The tag nucleic acid sequences may be random sequences that are not naturally occurring in the nucleic acid sample and do not cross hybridize to sequences naturally occurring in the nucleic acid sample. Methods of detecting the combination of tag sequences present in a sample, in parallel with methods of genetic analysis of the sample are disclosed. Kits containing marker molecules suitable for generating barcoded samples by mixing different combinations of marker molecules into each sample are also disclosed.Type: ApplicationFiled: September 19, 2005Publication date: April 6, 2006Applicant: Affymetrix, INC.Inventors: Frederick Christians, Rui Mei
-
Publication number: 20050123987Abstract: The presently claimed invention provides methods, compositions, and apparatus for analyzing nucleic acids isolated from blood. Specifically, the present invention provides a method of analyzing blood samples by blocking amplification of selected unwanted RNAs and subsequently analyzing the amplified sample by hybridization to a plurality of probes attached to a solid support. In one embodiment, the invention provides enriching for a population of interest in a complex population by diminishing the presence of an unwanted sequence that may interfere with the analysis of sequences of interest.Type: ApplicationFiled: January 21, 2005Publication date: June 9, 2005Applicant: Affymetrix, INC.Inventors: Frederick Christians, Rui Mei, Kai Wu, Charles Miyada
-
Patent number: 6884796Abstract: Certain novel sterol derivatives can be used for regulating the meiosis in oocytes and in male germ cells.Type: GrantFiled: June 4, 2002Date of Patent: April 26, 2005Assignees: NovoNordisk A/S, Schering AGInventors: Peter Faarup, Frederick Christian Grønvald, Thorsten Blume, Anthony Murray, Jens Breinholt
-
Publication number: 20050003369Abstract: The presently claimed invention provides methods, compositions, and apparatus for analyzing nucleic acids isolated from blood. Specifically, the present invention provides a method of analyzing blood samples by blocking amplification of selected unwanted RNAs and subsequently analyzing the amplified sample by hybridization to a plurality of probes attached to a solid support. In one embodiment, the invention provides enriching for a population of interest in a complex population by diminishing the presence of an unwanted sequence that may interfere with the analysis of sequences of interest.Type: ApplicationFiled: October 10, 2003Publication date: January 6, 2005Applicant: Affymetrix, INC.Inventors: Frederick Christians, Rui Mei, Kai Wu, Charles Miyada
-
Publication number: 20020183283Abstract: Certain novel sterol derivatives can be used for regulating the meiosis in oocytes and in male germ cells.Type: ApplicationFiled: June 4, 2002Publication date: December 5, 2002Inventors: Peter Faarup, Frederick Christian Gronvald, Thorsten Blume, Anthony Murray, Jens Breinholt
-
Patent number: 6407086Abstract: Certain novel sterol derivatives can be used for regulating the meiosis in oocytes and in male germ cells.Type: GrantFiled: January 12, 2001Date of Patent: June 18, 2002Assignees: Novo Nordisk A/S, Schering AktiengesellschaftInventors: Peter Faarup, Frederick Christian Grønvald, Thorsten Blume, Anthony Murray, Jens Breinholt
-
Publication number: 20020013302Abstract: Sterol derivative compounds, structurally related to natural compounds which can be extracted from bull testes and from human follicular fluid, useful for regulating meiosis in oocytes and in male germ cells. Some of these compounds are useful in the treatment of infertility, whereas other compounds are useful as contraceptives.Type: ApplicationFiled: June 11, 2001Publication date: January 31, 2002Inventors: Frederick Christian Gronvald, Peter Faarup, Erling Guddal
-
Publication number: 20010003782Abstract: Certain novel sterol derivatives can be used for regulating the meiosis in oocytes and in male germ cells.Type: ApplicationFiled: January 12, 2001Publication date: June 14, 2001Inventors: Peter Faarup, Frederick Christian Gronvald, Thorsten Blume, Anthony Murray, Jens Breinholt
-
Patent number: 5941571Abstract: In an element for a book which includes a sheet having a slit configured for receiving an item through the sheet, the improvement includes the slit going to two folds of the sheet along fold lines that are transverse to the slit, the folds being at angles that are 90 degrees or less.Type: GrantFiled: October 15, 1997Date of Patent: August 24, 1999Assignee: Specialty Loose Leaf, Inc.Inventors: Robert B. Wilson, Frederick Christian Schweitzer